利用两成分疾病活动评分评估类风湿关节炎中 TNF 抑制剂反应的药物遗传学
Pharmacogenetics of TNF inhibitor response in rheumatoid arthritis utilizing the two-component disease activity score.
机构信息
School of Medicine, University of Manchester, Manchester, M13 9PT, UK.
NIHR Manchester Biomedical Research Center, Central Manchester NHS Foundation Trust, Manchester Academic Health Science Center, Manchester, M13 9WL, UK.
出版信息
Pharmacogenomics. 2020 Nov;21(16):1151-1156. doi: 10.2217/pgs-2020-0043. Epub 2020 Oct 30.
Abstract
TNF inhibitor drugs are a treatment option for rheumatoid arthritis, but response is not universal. Response is typically measured using the composite 4-component (4C) disease activity score 28 (DAS28) which contains more subjective measures. This study used a validated 2-component (2C) DAS28 score to determine whether SNPs associated with response were replicated in the UK population. A literature review identified TNF inhibitor response SNPs. Linear regression was conducted to replicate associations with 4C or 2C-DAS28 response. Eighteen independent SNPs were analyzed in 1828 patients. One and four associations with 4C and 2C-DAS28 response respectively were identified (p ≤ 0.05). Further genetic associations were replicated using the 2C-DAS28 which may reflect the objective nature of 2C-AS28.
摘要
TNF 抑制剂药物是类风湿关节炎的一种治疗选择，但并非对所有人都有效。通常使用包含更多主观指标的复合 4 成分（4C）疾病活动评分 28（DAS28）来衡量反应。本研究使用经过验证的 2 成分（2C）DAS28 评分来确定与反应相关的单核苷酸多态性是否在英国人群中得到复制。通过文献回顾确定了 TNF 抑制剂反应 SNP。进行线性回归以复制与 4C 或 2C-DAS28 反应的关联。在 1828 名患者中分析了 18 个独立的 SNP。分别在 4C 和 2C-DAS28 反应中鉴定出 1 个和 4 个关联（p ≤ 0.05）。使用 2C-DAS28 进一步复制了遗传关联，这可能反映了 2C-AS28 的客观性质。
相似文献
1
Pharmacogenetics of TNF inhibitor response in rheumatoid arthritis utilizing the two-component disease activity score.利用两成分疾病活动评分评估类风湿关节炎中 TNF 抑制剂反应的药物遗传学
Pharmacogenomics. 2020 Nov;21(16):1151-1156. doi: 10.2217/pgs-2020-0043. Epub 2020 Oct 30.
2
Validation of GWAS-Identified Variants for Anti-TNF Drug Response in Rheumatoid Arthritis: A Meta-Analysis of Two Large Cohorts.GWAS 鉴定的抗 TNF 药物反应变异在类风湿关节炎中的验证：两个大型队列的荟萃分析。
Front Immunol. 2021 Oct 27;12:672255. doi: 10.3389/fimmu.2021.672255. eCollection 2021.
3
Correlation of C-reactive protein haplotypes with serum C-reactive protein level and response to anti-tumor necrosis factor therapy in UK rheumatoid arthritis patients: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort.英国类风湿性关节炎患者中C反应蛋白单倍型与血清C反应蛋白水平及抗肿瘤坏死因子治疗反应的相关性：类风湿性关节炎遗传学和基因组学研究联盟队列生物制剂研究结果
Arthritis Res Ther. 2012 Oct 7;14(5):R214. doi: 10.1186/ar4052.
4
A longitudinal genome-wide association study of anti-tumor necrosis factor response among Japanese patients with rheumatoid arthritis.一项针对日本类风湿性关节炎患者抗肿瘤坏死因子反应的全基因组纵向关联研究。
Arthritis Res Ther. 2016 Jan 18;18:12. doi: 10.1186/s13075-016-0920-6.
5
Pre-treatment calprotectin (MRP8/14) provides no added value to testing CRP alone in terms of predicting response to TNF inhibitors in rheumatoid arthritis in a post hoc analysis.在一项事后分析中，治疗前钙卫蛋白（MRP8/14）单独检测 CRP 并不能增加对类风湿关节炎患者对 TNF 抑制剂反应的预测价值。
Ann Rheum Dis. 2023 May;82(5):611-620. doi: 10.1136/ard-2022-222519. Epub 2023 Feb 21.
6
Lack of replication of genetic predictors for the rheumatoid arthritis response to anti-TNF treatments: a prospective case-only study.缺乏对 TNF 拮抗剂治疗类风湿关节炎反应的遗传预测因子的复制：一项前瞻性仅病例研究。
Arthritis Res Ther. 2010;12(2):R72. doi: 10.1186/ar2990. Epub 2010 Apr 27.
7
Association of the multi-biomarker disease activity score with joint destruction in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha inhibitor treatment in clinical practice.多生物标志物疾病活动评分与接受肿瘤坏死因子-α抑制剂治疗的类风湿关节炎患者关节破坏的相关性：临床实践研究。
Mod Rheumatol. 2016 Nov;26(6):850-856. doi: 10.3109/14397595.2016.1153449. Epub 2016 Mar 30.
8
Gene Polymorphisms as Potential Biomarkers of Disease Susceptibility and Response to TNF Inhibitors in Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Patients.基因多态性作为类风湿关节炎、强直性脊柱炎和银屑病关节炎患者疾病易感性和对 TNF 抑制剂反应的潜在生物标志物。
Front Immunol. 2021 Jun 11;12:631603. doi: 10.3389/fimmu.2021.631603. eCollection 2021.
9
Estimation of heritability of different outcomes for genetic studies of TNFi response in patients with rheumatoid arthritis.遗传研究中 TNF 抑制剂反应的不同结局的遗传力估计：类风湿关节炎患者的研究。
Ann Rheum Dis. 2015 Dec;74(12):2183-7. doi: 10.1136/annrheumdis-2014-205541. Epub 2014 Aug 11.
10
Previously reported PDE3A-SLCO1C1 genetic variant does not correlate with anti-TNF response in a large UK rheumatoid arthritis cohort.先前报道的PDE3A-SLCO1C1基因变异与英国一个大型类风湿性关节炎队列中的抗TNF反应不相关。
Pharmacogenomics. 2016 May;17(7):715-20. doi: 10.2217/pgs.16.16. Epub 2016 May 16.
引用本文的文献
1
Towards Personalized Medicine in Rheumatoid Arthritis.迈向类风湿关节炎的个性化医疗
Open Access Rheumatol. 2024 May 18;16:89-114. doi: 10.2147/OARRR.S372610. eCollection 2024.
2
Comprehensive genetic and functional analyses of Fc gamma receptors influence on response to rituximab therapy for autoimmunity.全面的 Fcγ 受体遗传和功能分析对自身免疫性疾病利妥昔单抗治疗反应的影响。
EBioMedicine. 2022 Dec;86:104343. doi: 10.1016/j.ebiom.2022.104343. Epub 2022 Nov 11.
3
Pharmacogenetics of Drug Therapies in Rheumatoid Arthritis.类风湿关节炎药物治疗的药物遗传学。
Methods Mol Biol. 2022;2547:527-567. doi: 10.1007/978-1-0716-2573-6_19.
本文引用的文献
1
Validity of a two-component imaging-derived disease activity score for improved assessment of synovitis in early rheumatoid arthritis.用于改善早期类风湿关节炎滑膜炎评估的双组分成像衍生疾病活动评分的有效性
Rheumatology (Oxford). 2019 Mar 1;58(8):1400-9. doi: 10.1093/rheumatology/kez049.
2
Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritis.类风湿关节炎中肿瘤坏死因子抑制剂治疗反应的全基因组关联研究。
Pharmacogenomics J. 2018 Sep;18(5):657-664. doi: 10.1038/s41397-018-0040-6. Epub 2018 Aug 31.
3
Systematic review and meta-analysis: pharmacogenetics of anti-TNF treatment response in rheumatoid arthritis.系统评价与荟萃分析：类风湿关节炎中抗TNF治疗反应的药物遗传学
Pharmacogenomics J. 2017 Oct;17(5):403-411. doi: 10.1038/tpj.2017.26. Epub 2017 Jun 13.
4
Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort.皮下注射抗肿瘤坏死因子药物治疗应答不佳的影响：来自类风湿关节炎生物制剂遗传学和基因组学研究联合会队列的结果。
Rheumatology (Oxford). 2015 Mar;54(3):494-9. doi: 10.1093/rheumatology/keu358. Epub 2014 Sep 10.
5
Estimation of heritability of different outcomes for genetic studies of TNFi response in patients with rheumatoid arthritis.遗传研究中 TNF 抑制剂反应的不同结局的遗传力估计：类风湿关节炎患者的研究。
Ann Rheum Dis. 2015 Dec;74(12):2183-7. doi: 10.1136/annrheumdis-2014-205541. Epub 2014 Aug 11.
6
The role of depression, anxiety, fatigue, and fibromyalgia on the evaluation of the remission status in patients with rheumatoid arthritis.抑郁、焦虑、疲劳和纤维肌痛对类风湿关节炎患者缓解状态评估的作用。
J Rheumatol. 2014 Sep;41(9):1755-60. doi: 10.3899/jrheum.131171. Epub 2014 Aug 1.
7
Development and validation of modified disease activity scores in rheumatoid arthritis: superior correlation with magnetic resonance imaging-detected synovitis and radiographic progression.改良的类风湿关节炎疾病活动评分的制定与验证：与磁共振成像检测到的滑膜炎和放射学进展相关性更好。
Arthritis Rheumatol. 2014 Apr;66(4):794-802. doi: 10.1002/art.38304.
8
Genetics of rheumatoid arthritis contributes to biology and drug discovery.类风湿关节炎的遗传学研究有助于生物学和药物发现。
Nature. 2014 Feb 20;506(7488):376-81. doi: 10.1038/nature12873. Epub 2013 Dec 25.
9
Impact of psychological factors on subjective disease activity assessments in patients with severe rheumatoid arthritis.心理因素对严重类风湿关节炎患者主观疾病活动评估的影响。
Arthritis Care Res (Hoboken). 2014 Jun;66(6):861-8. doi: 10.1002/acr.22249.
10
Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis.全基因组关联研究和基因表达分析鉴定 CD84 为类风湿关节炎对依那西普治疗反应的预测因子。
PLoS Genet. 2013 Mar;9(3):e1003394. doi: 10.1371/journal.pgen.1003394. Epub 2013 Mar 28.
Zotero 插件